Serving the Society Since 1986

疫苗与抗病毒专题 | VS年度盘点 (2019-2020)

1. Development of Improved Mumps Vaccine Candidates by Mutating Viral mRNA Cap Methyltransferase Sites in the Large Polymerase Protein
Hao X, Wang Y, Zhu M, Zhou D, Liu R, Wang B, Huang YW, Zhao Z.
Virol Sin. 2020 Dec 7:1–16. doi:10.1007/s12250-020-00326-y. Epub ahead of print.

2. Seroprevalence of Neutralizing Antibodies against Six Human Adenovirus Types Indicates the Low Level of Herd Immunity in Young Children from Guangzhou, China
Tian X, Fan Y, Wang C, Liu Z, Liu W, Xu Y, Mo C, You A, Li X, Rong X, Zhou R.
Virol Sin. 2020 Nov 9:1–9. doi: 10.1007/s12250-020-00307-1. Epub ahead of print.

3. Repurposing of Antazoline Hydrochloride as an Inhibitor of Hepatitis B Virus DNA Secretion
Li J, Hu Y, Yuan Y, Zhao Y, Han Q, Liu C, Hu X, Zhou Y, Wang Y, Guo Y, Wu C, Chen X, Pei R.
Virol Sin. 2020 Nov 9. doi:10.1007/s12250-020-00306-2. Epub ahead of print.

4. Inhibitory Activity of Honeysuckle Extracts against Influenza A Virus In Vitro and In Vivo
Li M, Wang Y, Jin J, Dou J, Guo Q, Ke X, Zhou C, Guo M.
Virol Sin. 2020 Oct 12. doi: 10.1007/s12250-020-00302-6. Epub ahead of print.

5. From Monovalent to Multivalent Vaccines, the Exploration for Potential Preventive Strategies Against Hand, Foot, and Mouth Disease (HFMD)
He X, Zhang M, Zhao C, Zheng P, Zhang X, Xu J.
Virol Sin. 2020 Sep 30:1–9. doi:10.1007/s12250-020-00294-3. Epub ahead of print.

6. A Highly Attenuated Mumps Virus Strain of Genotype F Generated by Passaging in Vero Cells
Zhang Y, Xie L, Chai B, Ruan J, Gu Y, Niu B, Zhang Y, Fu Z, An Q, Tian D.
Virol Sin. 2020 Sep 29. doi: 10.1007/s12250-020-00292-5. Epub ahead of print.

7. Porcine Immunoglobulin Fc Fused P30/P54 Protein of African Swine Fever Virus Displaying on Surface of S. cerevisiae Elicit Strong Antibody Production in Swine
Chen C, Hua D, Shi J, Tan Z, Zhu M, Tan K, Zhang L, Huang J.
Virol Sin. 2020 Sep 11. doi: 10.1007/s12250-020-00278-3. Epub ahead of print.

8. Characterizing the Lassa Virus Envelope Glycoprotein Membrane Proximal External Region for Its Role in Fusogenicity
Cao J, Zhang G, Zhou M, Liu Y, Xiao G, Wang W.
Virol Sin. 2020 Sep 8. doi: 10.1007/s12250-020-00286-3. Epub ahead of print.

9. SARS-CoV-2 Serological Survey of Cats in China before and after the Pandemic.
Deng J, Liu Y, Sun C, Bai J, Sun J, Hao L, Li X, Tian K.
Virol Sin. 2020 Sep 1:1–3. doi: 10.1007/s12250-020-00284-5. Epub ahead of print.

10. Flu Universal Vaccines: New Tricks on an Old Virus.
Du R, Cui Q, Rong L.
Virol Sin. 2020 Sep 1:1–12. doi: 10.1007/s12250-020-00283-6. Epub ahead of print.

11. Identification of Aristolactam Derivatives That Act as Inhibitors of Human Immunodeficiency Virus Type 1 Infection and Replication by Targeting Tat-Mediated Viral Transcription
Shin Y, Park CM, Kim HG, Kim DE, Choi MS, Kim JA, Choi BS, Yoon CH.
Virol Sin. 2020 Aug 10. doi:10.1007/s12250-020-00274-7. Epub ahead of print.

12. Immune Responses to Varicella-Zoster Virus Glycoprotein E Formulated with Poly(Lactic-co-Glycolic Acid) Nanoparticles and Nucleic Acid Adjuvants in Mice
Wang Y, Qi J, Cao H, Liu C.
Virol Sin. 2020 Aug 5. doi:10.1007/s12250-020-00261-y. Epub ahead of print.

13. Freeze-Drying Formulations Increased the Adenovirus and Poxvirus Vaccine Storage Times and Antigen Stabilities
Chen Y, Liao Q, Chen T, Zhang Y, Yuan W, Xu J, Zhang X.
Virol Sin. 2020 Jul 21:1–8. doi:10.1007/s12250-020-00250-1. Epub ahead of print.

14. Monitoring Neutralization Property Change of Evolving Hantaan and Seoul Viruses with a Novel Pseudovirus-Based Assay.
Ning T, Wang L, Liu S, Ma J, Nie J, Huang W, Li X, Li Y, Wang Y.
Virol Sin. 2020 Jun 12. doi:10.1007/s12250-020-00237-y. Epub ahead of print.

15. Concerns on Vaccine against Varicella Caused by Varicella-Zoster Virus Infection
Zeng WB, Zhang F, Cheng S, Sun JY, Shen H, Luo MH.
Virol Sin. 2020 May 28. doi: 10.1007/s12250-020-00231-4. Epub ahead of print.

16. Construction and Characterization of a Novel Recombinant Attenuated and Replication-Deficient Candidate Human Adenovirus Type 3 Vaccine: "Adenovirus Vaccine Within an Adenovirus Vector".
Yan Y, Jing S, Feng L, Zhang J, Zeng Z, Li M, Zhao S, Ou J, Lan W, Guan W, Wu X, Wu J, Seto D, Zhang Q.
Virol Sin. 2020 May 26:1–11. doi: 10.1007/s12250-020-00234-1. Epub ahead of print.

17. Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19.
Chen J, Huang R, Nie Y, Wen X, Wu Y.
Virol Sin. 2020(6). doi: 10.1007/s12250-020-00327-x.

18. Dynamic Changes of Antibodies to SARS-CoV-2 in COVID-19 Patients at Early Stage of Outbreak
Shu H, Wang S, Ruan S, Wang Y, Zhang J, Yuan Y, Liu H, Wu Y, Li R, Pan S, Ouyang Y, Yuan S, Zhou P, Shang Y.
Virol Sin. 2020(6). doi: 10.1007/s12250-020-00268-5. Epub ahead of print.

19. Viral and Antibody Kinetics of COVID-19 Patients with Different Disease Severities in Acute and Convalescent Phases: A 6-Month Follow-Up Study
Zhang X, Lu S, Li H, Wang Y, Lu Z, Liu Z, Lai Q, Ji Y, Huang X, Li Y, Sun J, Wu Y, Xu X, Hou J.
Virol Sin. 2020(6). doi: 10.1007/s12250-020-00329-9.

20. A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial
Hu K, Wang M, Zhao Y, Zhang Y, Wang T, Zheng Z, Li X, Zeng S, Zhao D, Li H, Xu K, Lan K.
Virol Sin. 2020(6). doi: 10.1007/s12250-020-00258-7

21. Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study
Wu Y, Hong K, Ruan L, Yang X, Zhang J, Xu J, Pan S, Ren L, Chen L, Huang C, Shang Y.
Virol Sin. 2020(6). doi: 10.1007/s12250-020-00281-8.

22. Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro
Zhang L, Liu J, Cao R, Xu M, Wu Y, Shang W, Wang X, Zhang H, Jiang X, Sun Y, Hu H, Li Y, Zou G, Zhang M, Zhao L, Li W, Guo X, Zhuang X, Yang XL, Shi ZL, Deng F, Hu Z, Xiao G, Wang M, Zhong W.
Virol Sin. 2020(6). doi: 10.1007/s12250-020-00288-1.

23. COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine
Guan W, Lan W, Zhang J, Zhao S, Ou J, Wu X, Yan Y, Wu J, Zhang Q.
Virol Sin. 2020(6). doi: 10.1007/s12250-020-00297-0.

24. Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit
Cai Y, Xu W, Gu C, Cai X, Qu D, Lu L, Xie Y, Jiang S.
Virol Sin. 2020(6). doi: 10.1007/s12250-020-00305-3. Epub ahead of print.

25. Baculovirus Surface Display of Zika Virus Envelope Protein Protects against Virus Challenge in Mouse Model
Luo D, Miao Y, Ke X, Tan Z, Hu C, Li P, Wang T, Zhang Y, Sun J, Liu Y, Wang H, Zheng Z.
Virol Sin. 2020(5):637-650. doi:10.1007/s12250-020-00238-x.

26. Chimeric Newcastle Disease Virus-like Particles Containing DC-Binding Peptide-Fused Haemagglutinin Protect Chickens from Virulent Newcastle Disease Virus and H9N2 Avian Influenza Virus Challenge
Xu X, Qian J, Qin L, Li J, Xue C, Ding J, Wang W, Ding W, Yin R, Jin N, Ding Z.
Virol Sin. 2020(4):455-467. doi: 10.1007/s12250-020-00199-1.

27. Structure of the HRV-C 3C-Rupintrivir Complex Provides New Insights for Inhibitor Design
Yuan S, Fan K, Chen Z, Sun Y, Hou H, Zhu L.
Virol Sin. 2020(4):445-454. doi: 10.1007/s12250-020-00196-4.

28. SARS-Coronavirus-2 Nsp13 Possesses NTPase and RNA Helicase Activities That Can Be Inhibited by Bismuth Salts
Shu T, Huang M, Wu D, Ren Y, Zhang X, Han Y, Mu J, Wang R, Qiu Y, Zhang DY, Zhou X.
Virol Sin. 2020(3):321-329. doi:10.1007/s12250-020-00242-1.

29. Clinical Features and Treatment of 2019-nCov Pneumonia Patients in Wuhan: Report of A Couple Cases
Zhang Z, Li X, Zhang W, Shi ZL, Zheng Z, Wang T.
Virol Sin. 2020(3):330-336. doi:10.1007/s12250-020-00203-8

30. mRNA Vaccines: Possible Tools to Combat SARS-CoV-2
Yi C, Yi Y, Li J.
Virol Sin. 2020(3):259-262. doi: 10.1007/s12250-020-00243-0.

31. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools
Fu Y, Cheng Y, Wu Y.
Virol Sin. 2020(3):266-271. doi: 10.1007/s12250-020-00207-4.

32. Old Weapon for New Enemy: Drug Repurposing for Treatment of Newly Emerging Viral Diseases
Guo D.
Virol Sin. 2020(3):253-255. doi:10.1007/s12250-020-00204-7.

33. Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoV-Induced Acute Lung Injury
Wu Y.
Virol Sin. 2020(3):256-258. doi:10.1007/s12250-020-00205-6.

34. Computational Identification of Small Interfering RNA Targets in SARS-CoV-2
Chen W, Feng P, Liu K, Wu M, Lin H.
Virol Sin. 2020(3):359-361. doi:10.1007/s12250-020-00221-6.

35. Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection
Liu Z, Xia S, Wang X, Lan Q, Xu W, Wang Q, Jiang S, Lu L.
Virol Sin. 2020(3):340-343. doi: 10.1007/s12250-020-00214-5.

36. A Deleted Deletion Site in a New Vector Strain and Exceptional Genomic Stability of Plaque-Purified Modified Vaccinia Ankara (MVA)
Jordan I, Horn D, Thiele K, Haag L, Fiddeke K, Sandig V.
Virol Sin. 2020(2):212-226. doi:10.1007/s12250-019-00176-3.

37. Screening and Identification of Marburg Virus Entry Inhibitors Using Approved Drugs
Zhang L, Lei S, Xie H, Li Q, Liu S, Liu Q, Huang W, Xiao X, Wang Y.
Virol Sin. 2020(2):235-239. doi: 10.1007/s12250-019-00184-3.

38. Monoclonal Antibody-Based Serological Detection of Rice Stripe Mosaic Virus Infection in Rice Plants or Leafhoppers
Guo L, Wu J, Chen R, Hong J, Zhou X, Wu J.
Virol Sin. 2020(2):227-234. doi: 10.1007/s12250-019-00186-1.

39. Cryo-EM Studies of Virus-Antibody Immune Complexes
Li N, Li Z, Fu Y, Cao S.
Virol Sin. 2020(1):1-13. doi: 10.1007/s12250-019-00190-5.

1. Reducing Viral Inhibition of Host Cellular Apoptosis Strengthens the Immunogenicity and Protective Efficacy of an Attenuated HSV-1 Strain
Xu X, He Y, Fan S, Feng M, Jiang G, Wang L, Zhang Y, Liao Y, Li Q.
Virol Sin. 2019(6):673-687. doi: 10.1007/s12250-019-00156-7.

2. Nsp2 and GP5-M of Porcine Reproductive and Respiratory Syndrome Virus Contribute to Targets for Neutralizing Antibodies
Su J, Zhou L, He B, Zhang X, Ge X, Han J, Guo X, Yang H.
Virol Sin. 2019(6):631-640. doi:10.1007/s12250-019-00149-6.

3. The Establishment and Validation of the Human U937 Cell Line as a Cellular Model to Screen Immunomodulatory Agents Regulating Cytokine Release Induced by Influenza Virus Infection
Liu G, Chen S, Hu A, Zhang L, Sun W, Chen J, Tang W, Zhang H, Liu C, Ke C, Chen X.
Virol Sin. 2019(6):648-661. doi:10.1007/s12250-019-00145-w.

4. A Recombinant Rabies Virus Expressing Fms-like Tyrosine Kinase 3 Ligand (Flt3L) Induces Enhanced Immunogenicity in Mice
Zhang Y, Yang J, Li M, Cui M, Fu ZF, Zhao L, Zhou M.
Virol Sin. 2019(6):662-672. doi:10.1007/s12250-019-00144-x.

5. A Novel DT40 Antibody Library for the Generation of Monoclonal Antibodies
Wang B, Wang F, Huang H, Zhao Z.
Virol Sin. 2019(6):641-647. doi:10.1007/s12250-019-00142-z.

6. Development of a Specific CHIKV-E2 Monoclonal Antibody for Chikungunya Diagnosis
Kim J, Yang J, Kim YB, Lee HJ, Kim S, Poo H.
Virol Sin. 2019(5):563-571. doi: 10.1007/s12250-019-00135-y.

7. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats
Wang W, Huang B, Wang X, Tan W, Ruan L.
Virol Sin. 2019(5):583-591. doi:10.1007/s12250-019-00138-9.

8. Proteasome Inhibitor PS-341 Effectively Blocks Infection by the Severe Fever with Thrombocytopenia Syndrome Virus
Liu S, Liu H, Zhang K, Li X, Duan Y, Wang Z, Wang T.
Virol Sin. 2019(5):572-582. doi:10.1007/s12250-019-00162-9.

9. Complementation of Wild-Type and Drug-Resistant Hepatitis B Virus Genomes to Maintain Viral Replication and Rescue Virion Production under Nucleos(t)ide Analogs
Wu C, Li B, Zhang X, Zhao K, Chen Y, Yuan Y, Liu Y, Chen R, Xu D, Chen X, Lu M.
Virol Sin. 2019(4):377-385. doi: 10.1007/s12250-019-00143-y.

10. Establishment of Novel Monoclonal Fabs Specific for Epstein-Barr Virus Encoded Latent Membrane Protein 1
Li G, Ding L, Ma X, Cai Q, Ying T, Wei F.
Virol Sin. 2019(4):467-470. doi: 10.1007/s12250-019-00103-6.

11. Decreases in Both the Seroprevalence of Serum Antibodies and Seroprotection against Japanese Encephalitis Virus among Vaccinated Children
Wang R, Xie L, Gao N, Fan D, Chen H, Wang P, Zhou H, An J.
Virol Sin. 2019(3):243-252. doi: 10.1007/s12250-019-00099-z.

12. Inhibition of Herpes Simplex Virus-1 Replication by Natural Compound Honokiol
Liu S, Li L, Tan L, Liang X.
Virol Sin. 2019(3):315-323. doi: 10.1007/s12250-019-00104-5.

13. Interferon as a Mucosal Adjuvant for an Influenza Vaccine in Pigs
Liu L, Fan W, Zhang H, Zhang S, Cui L, Wang M, Bai X, Yang W, Sun L, Yang L, Liu W, Li J.
Virol Sin. 2019(3):324-333. doi: 10.1007/s12250-019-00102-7.

14. Boosting Global Yellow Fever Vaccine Supply for Epidemic Preparedness: 3 Actions for China and the USA
Lucey DR, Kent KR.
Virol Sin. 2019(3):235-239. doi: 10.1007/s12250-019-00129-w.

15. Localization Analysis of Heterophilic Antigen Epitopes of H1N1 Influenza Virus Hemagglutinin
Guo CY, Zhang HX, Zhang JJ, Sun LJ, Li HJ, Liang DY, Feng Q, Li Y, Feng YM, Xie X, Hu J.
Virol Sin. 2019(3):306-314. doi:10.1007/s12250-019-00100-9.

16. Identification of a Novel Universal Potential Epitope on the Cytoplasmic Tail of H7N9 Virus Hemagglutinin
Liu X, Ding L, Yuan J, Liao J, Duan L, Wang W, Tan W, Yu W, Zhou B, Chen X, Yang Z.
Virol Sin. 2019(3):334-337. doi:10.1007/s12250-019-00110-7.

17. Development of Neutralizing Antibodies against Zika Virus Based on Its Envelope Protein Structure
Yang C, Gong R, de Val N.
Virol Sin. 2019(2):168-174. doi: 10.1007/s12250-019-00093-5.

18. Oxymatrine Inhibits Bocavirus MVC Replication, Reduces Viral Gene Expression and Decreases Apoptosis Induced by Viral Infection
Ding Y, Li N, Sun J, Zhang L, Guo J, Hao X, Sun Y.
Virol Sin. 2019(1):78-87. doi: 10.1007/s12250-019-00088-2

19. Electroporation-Mediated Immunization of a Candidate DNA Vaccine Expressing Dengue Virus Serotype 4 prM-E Antigen Confers Long-Term Protection in Mice
Sheng Z, Chen H, Feng K, Gao N, Wang R, Wang P, Fan D, An J.
Virol Sin. 2019(1):88-96. doi: 10.1007/s12250-019-00090-8.

20. A Vesicular Stomatitis Virus-Based Vaccine Carrying Zika Virus Capsid Protein Protects Mice from Viral Infection
Shi X, Hu J, Guo J, Wu C, Xiong S, Dong C.
Virol Sin. 2019(1):106-110. doi: 10.1007/s12250-019-00083-7.

  • 分享到:
38卷第2期 (2023年4月)

ISSN 1674-0769

EISSN 1995-820X

CN 42-1760/Q

主编: 石正丽

影响因子: 6.947*


Submit Manuscript

Focused Topic